How Red Wine May Reduce the Incidence of Alzheimer's

Alzheimer's researchers at UCLA have now discovered how red wine may reduce the incidence of Alzheimer's. Scientists call it the "French paradox", a society that, despite consuming food high in cholesterol and saturated fats, has long had low death rates from heart disease.

Research has suggested that red wine consumed with fatty food may be beneficial not only for cardiovascular health but in preventing certain tumors and even Alzheimer's.

David Teplow, a UCLA professor of neurology, and colleagues show how naturally occurring compounds in red wine called polyphenols block the formation of proteins that build the toxic plaques thought to destroy brain cells, and also how they reduce the toxicity of existing plaques, thus reducing cognitive deterioration.

Polyphenols comprise a chemical class with more than 8,000 members, many of which are found in high concentrations in wine, tea, nuts, berries, cocoa and various plants.

Past research has suggested that such polyphenols may inhibit or prevent the buildup of toxic fibers composed primarily of two proteins, Aß40 and Aß42, that deposit in the brain and form the plaques which have long been associated with Alzheimer's. Until now, however, no one understood the mechanics of how polyphenols worked.

Teplow's lab has been studying how amyloid beta (Aß) is involved in causing Alzheimer's. In this work, researchers monitored how Aß40 and Aß42 proteins folded up and stuck to each other to produce aggregates that killed nerve cells in mice. They then treated the proteins with a polyphenol compound extracted from grape seeds. They discovered that polyphenols not only blocked the formation of the toxic aggregates of Aß, but also decreased toxicity when they were combined with Aß before it was added to brain cells.

"What we found is pretty straightforward," Teplow said. "If the Aß proteins can't assemble, toxic aggregates can't form, and thus there is no toxicity. Our work in the laboratory, and Mt. Sinai's Dr. Giulio Pasinetti's work in mice, suggest that administration of the compound to Alzheimer's patients might block the development of these toxic aggregates, prevent Alzheimer’s disease development and also ameliorate existing Alzheimer's."

"No disease-modifying treatments of Alzheimer's now exist, and initial clinical trials of a number of different candidate drugs have been disappointing," Teplow said. "So we believe that human clinical trials are an important next step."

Related Articles

Diabetes and Alzheimer's Connections Explored

In a special issue of the Journal of Alzheimer's Disease, nineteen contributions examine the possible connections between Alzheimer's disease and type 2

Scientists Make Headway in Understanding Alzheimer's

Scientists have discovered that a protein called BAG2 is important for understanding Alzheimer's and may open up new targets for treatment. They are ready to move

Test to Identify if Early Dementia Will Develop into Alzheimer's

Researchers have found that a combination of proteins in the cerebrospinal fluid can reliably identify which patients with early symptoms of dementia will

Older People Who Have "Mental Lapses" More Likely to Have Alzheimer's

Older people who have "mental lapses" may be more likely to have Alzheimer's disease than people who do not have these

Gene Variation Linked to Lower Dementia and Alzheimer’s Disease Risk

Preliminary research suggests that variation of a gene for a plasma protein is associated with slower age-related memory decline and a lower risk of dementia and

References:
1. David Teplow, et al. Red, red wine: How it fights Alzheimer's. The UCLA Department of Neurology. November 2008.
2. Image by RINAJO.DK